Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.
Müller-Vahl et al.·NeuropsychopharmacologyImpact 4.4
Kein Nutzen nachgewiesenGRADEModerat107 Zitate
Stichproben = 24 Pat.
Dauer6 Wochen plus 5–6 Wochen…
KontrollePlacebo
EndpunktNeuropsychologische Leistung
Verblindungdoppelblind
DesignRCT (doppelblind, placebokontrolliert)
Cannabinoidthc
Max. Dosis10.0 mg
Applikationoral
”Kernaussage
Delta-9-THC hatte keinen negativen Einfluss auf die neuropsychologische Leistungsfähigkeit bei Tourette-Patienten.
Zusammenfassung
n=24 Tourette-Patienten, Delta-9-THC bis 10 mg über 6 Wochen vs. Placebo; kein negativer Einfluss auf Lernkurve, Interferenz, Recall, visuelles Gedächtnis oder geteilte Aufmerksamkeit; Trend zu signifikanter Verbesserung des unmittelbaren verbalen Gedächtnisses unter THC (p-Wert im Trend); THC zeigt weder akute noch Langzeit-Kognitionsdefizite bei TS-Patienten.
P
PopulationErwachsene mit Tourette-Syndrom, n=24
I
InterventionDelta-9-THC oral bis 10 mg/Tag über 6 Wochen
C
KontrollePlacebo
O
OutcomeKein nachteiliger Effekt auf neuropsychologische Leistung (Lernkurve, Interferenz, Gedächtnis, geteilte Aufmerksamkeit); Trend zur Verbesserung des unmittelbaren verbalen Gedächtnisses
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Moderat
Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.
Previous studies provide evidence that Cannabis (Cannabis sativa) and delta-9-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive ingredient of Cannabis, respectively, are effective in the treatment of tics and behavioral problems in Tourette syndrome (TS). It, therefore, has been speculated that the central cannabinoid receptor system might be involved in TS pathology. However, in healthy Cannabis users there is an ongoing debate as to whether the use of cannabis causes acute and/or long-term cognitive deficits. In this randomized double-blind placebo-controlled study, we investigated the effect of a treatment with up to 10 mg Delta(9)-THC over a 6-week period on neuropsychological performance in 24 patients suffering from TS. During medication and immediately as well as 5-6 weeks after withdrawal of Delta(9)-THC treatment, no detrimental effect was seen on learning curve, interference, recall and recognition of word lists, immediate visual memory span, and divided attention. Measuring immediate verbal memory span, we even found a trend towards a significant improvement during and after treatment. Results from this study corroborate previous data suggesting that in patients suffering from TS, treatment with Delta(9)-THC causes neither acute nor long-term cognitive deficits. Larger and longer-duration controlled studies are recommended to provide more information on the adverse effect profile of THC in patients suffering from TS.